-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

615.O3.6 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Outcomes and New Treatment Strategies in Genetically Adverse Risk and MRD-positive AML

Symposia: Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, adult, Biological therapies, AML, Non-Biological therapies, elderly, Clinical Research, Chemotherapy, Combination therapy, pediatric, Diseases, neonatal, Therapies, therapy sequence, real-world evidence, registries, Myeloid Malignancies, Technology and Procedures, Study Population, Human, Minimal Residual Disease , Transplantation, molecular testing
Sunday, December 11, 2022: 4:30 PM-6:00 PM
343-345 (Ernest N. Morial Convention Center)
Moderators:
Jacob M. Rowe, MB, BS, Shaare Zedek Medical Center and Terrence Bradley, MD, University of Miami Sylvester Comprehensive Cancer Center
Disclosures:
Rowe: Biosight: Consultancy.
This session includes six abstracts describing both clinical outcomes and new treatment approaches in patients with genetically adverse risk and MRD-positive AML.
4:30 PM

Jundan Xie1*, Xiaofei Yang, MD, PhD1*, Xiebing Bao, MD1*, Hongjie Shen, MD, PhD1*, Jiannong Cen, BS1*, Li Yao, MD, PhD1*, Xiaohui Hu, MD, PhD2*, Qian Wu, MD1*, Jingren Zhang, MD1*, Xuefeng He, MD, PhD2*, Xiaowen Tang, MD, PhD1*, AiNing Sun1*, Hongchun Qiu, MD, PhD3*, Shengli Xue1*, Ying Wang, MD, PhD1*, Jianhong Fu, MD, PhD1*, Huiying Qiu, MD, PhD1*, Depei Wu1 and Suning Chen, MD, PhD1*

1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, China
2Hongci Hospital, Suzhou, China
3Department of Hematology, Kunshan Third People's Hospital, Kunshan, China

4:45 PM

Hartmut Döhner, MD1, Keith W. Pratz, MD2, Courtney D. DiNardo, MD, MSCE3, Brian A. Jonas, MD, PhD4, Vinod A. Pullarkat, MD5*, Michael J. Thirman, MD6, Christian Recher, MD7, Andre C. Schuh, MD8, Sunil Babu, MD9*, Monique Dail, PhD10*, Grace Ku, MD10, Yan Sun, PhD11*, Jalaja Potluri, MD11, Brenda Chyla, PhD11 and Daniel A. Pollyea, MD12

1Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
2Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Internal Medicine, Division of Malignant Hematology, Transplantation and Cellular Therapy, University of California Davis School of Medicine, Sacramento, CA
5Department of Hematology and Hematopoietic Cell Transplantation and Gehr Family Center for Leukemia Research, City of Hope Comprehensive Cancer Center, Duarte, CA
6Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
7Service d'Hématologie, CHU de Toulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
8Princess Margaret Cancer Centre, Toronto, ON, Canada
9Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN
10Genentech Inc., South San Francisco, CA
11AbbVie Inc., North Chicago, IL
12Division of Hematology, University of Colorado School of Medicine, Aurora, CO

5:00 PM

Naval Daver, MD1, Shahed Iqbal, PhD, MBBS, MPH2*, Julie Huang3*, Camille Renard, MSc4*, Joyce Lin3*, Harry Pan5*, Guan Xing, PhD4*, Yang Pan, PhD4* and Giri Ramsingh4*

1MD Anderson Cancer Center, Houston, TX
2Gilead Sciences, Inc., FOSTER CITY, CA
3Gilead Sciences, Inc., Foster City
4Gilead Sciences, Inc., Foster City, CA
5Gilead Sciences, Inc, Foster City

5:15 PM

Akriti G Jain, MD1, Somedeb Ball, MD2, Luis E. E. Aguirre, MD2, Andrew Kuykendall, MD2, Onyee Chan, MD2*, Rami S. Komrokji, MD2, Eric Padron, MD2, David A. Sallman, MD3, Jeffrey E. Lancet, MD2, Asmita Mishra, MD4 and Kendra Sweet, MD2

1Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, WESLEY CHAPEL, FL
2Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
3Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

5:30 PM

Daisuke Tomizawa, MD, PhD1, Shiro Tanaka, PhD2*, Shotaro Iwamoto, MD3*, Hidefumi Hiramatsu, MD, PhD4, Jun Matsubayashi, PhD5*, Daisuke Hasegawa, MD, PhD6*, Hiroshi Moritake, MD, PhD7, Daiichiro Hasegawa, MD, PhD8, Kiminori Terui, MD, PhD9*, Asahito Hama, MD, PhD10*, Shin-ichi Tsujimoto, MD, PhD11*, Nobutaka Kiyokawa, MD, PhD12*, Hayato Miyachi, MD, PhD13*, Takao Deguchi, MD, PhD14,15, Yoshiko Hashii, MD, PhD16,17, Yuka Iijima-Yamashita, PhD18*, Tomohiko Taki, MD, PhD19, Yasushi Noguchi, MD20*, Kazutoshi Koike, MD21*, Katsuyoshi Koh22*, Yuki Yuza, MD, PhD23*, Akiko Moriya Saito, MD, PhD18*, Keizo Horibe, MD, PhD18*, Takashi Taga, MD, PhD24* and Souichi Adachi, MD, PhD25

1Division of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan
2Department of Clinical Biostatistics, Graduate School of Medicine, Kyoto University, Kyoto, Japan
3Department of Pediatrics, Mie University Graduate School of Medicine, Tsu, Japan
4Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan
5Center for Clinical Research and Advanced Medicine, Shiga University of Medical Science, Otsu, Japan
6Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan
7Division of Pediatrics, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
8Department of Hematology and Oncology, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan
9Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
10Department of Hematology and Oncology, Children’s Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital, Nagoya, Nagoya, Japan
11Department of Pediatrics, Yokohama City University, Yokohama, Japan
12Department of Pediatric Hematology and Oncology Research, Research Institute, National Center for Child Health and Development, Tokyo, Japan
13Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, Japan
14Division of Cancer Immunodiagnostics, Children’s Cancer Center, National Center for Child Health and Development, Tokyo, Japan
15Department of Pediatrics, Mie University Graduate School of Medicine, Tsu, TKY, Japan
16Department of Immunotherapy, Osaka University Graduate School of Medicine, Muko, KYO, Japan
17Department of Pediatrics, Osaka International Cancer Institute, Osaka, Japan
18Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
19Department or Medical Technology, Kyorin University Faculty of Health Sciences, Tokyo, Japan
20Department of Pediatrics, Japanese Red Cross Narita Hospital, Chiba, Japan
21Ibaraki Children's Hospital, Mito, Japan
22Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan
23Department of Hematology-Oncology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan
24Department of Pediatrics, Shiga University of Medical Science, Otsu, Japan
25Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan

5:45 PM

Ing S Tiong, FRACP, FRCPA, MPhil1,2,3, Devendra Hiwase, MD, MBBS, PhD, FRACP, FRCPA4,5, Emad Uddin Abro, MBBS, FRACP, FRCPA, BSc(Hons)6*, Ashish Bajel, MBBS, DM7, Emma Palfreyman, MBBS, FRACP, FRCPA8*, Sun Loo, MBBS, FRACP, FRCPA9,10, Shaun Fleming, FRACP FRCPA2*, Chun Yew Fong, MBBS, PhD, FRACP, FRCPA11, Tse-Chieh Teh, MBBS, PhD, FRACP, FRCPA12,13*, Adam Ivey, BSc, MSc, PhD12* and Andrew H Wei, MBBS, PhD2,14

1Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Melbourne, VIC, Australia
2The Alfred Hospital and Monash University, Melbourne, VIC, Australia
3Austin Health and Olivia Newton John Cancer Research Institute, Melbourne, Australia
4Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia
5Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia
6Department of Haematology, Princess Alexandra Hospital, Brisbane, Australia
7Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia
8Royal Darwin Hospital, Northern Territory, Australia
9Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia
10The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
11Austin Health and Olivia Newton John Cancer Research Institute, Melbourne, VIC, Australia
12The Alfred Hospital and Monash University, Melbourne, Australia
13Box Hill Hospital, Victoria, Australia
14Department of Clinical Haematology, Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Melbourne, VIC, Australia

*signifies non-member of ASH